Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Reata Pharma has been acquired by Biogen. This page is no longer monitored and will soon be closed. Reata Pharmaceuticals, Inc. Pronnounced /ree-AH-tah/
(8)

(Nasdaq:RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Address

5320 Legacy Drive
Plano, TX
75024

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

(972) 865-2219

Website

https://www.reatapharma.com/social-media-disclosure/default.aspx

Alerts

Be the first to know and let us send you an email when Reata Pharmaceuticals, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Reata Pharmaceuticals, Inc.:

Shortcuts

Share

Category